Calcium antagonist treatment by lercanidipine prevents hyperpolarization in essential hypertension

Hypertension

Volumn 41, Issue 4, 2003, Pages 950-955

  Taddei, Stefano ^a   Virdis, Agostino ^a   Ghiadoni, Lorenzo ^a   Versari, Daniele ^a   Salvetti, Guido ^a   Magagna, Armando ^a   Salvetti, Antonio ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Antioxidants; Calcium antagonists; Endothelium; Endothelium derived factors; Free radicals; Hypertension, essential; Nitric oxide

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM) INHIBITOR; ANTIOXIDANT; ASCORBIC ACID; BRADYKININ; CALCIUM ANTAGONIST; CALCIUM CHANNEL; CHOLESTEROL; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ISOPROSTANE; LERCANIDIPINE; LIPID PEROXIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; N(G) METHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; NITROPRUSSIDE SODIUM; OUABAIN; TRIACYLGLYCEROL;

ADULT; ANTIOXIDANT ACTIVITY; ARM BLOOD FLOW; ARTICLE; CARDIOVASCULAR EFFECT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HYPERPOLARIZATION; HYPERTENSION; MALE; OXIDATIVE STRESS; PLETHYSMOGRAPHY; PRIORITY JOURNAL; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM; VASODILATATION;

ANTIOXIDANTS; ASCORBIC ACID; CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; ENDOTHELIUM, VASCULAR; FEMALE; FOREARM; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NITRIC OXIDE; OXIDATIVE STRESS; REGIONAL BLOOD FLOW; VASODILATION;

EID: 0037388639     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000063361.70525.3C     Document Type: Article

References (49)

1. Luscher TF, Vanhoutte PM. The Endothelium: Modulator of Cardiovascular Function. Boca Raton, Fla: CRC Press; 1990.
2. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327:524-526.
3. Cohen RA, Vanhoutte PM. Endothelium-dependent hyperpolarization: beyond nitric oxide and cyclic GMP. Circulation. 1995;92:3337-3349.
4. Luscher TF, Vanhoutte PM. Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. Hypertension. 1986;8:344-348.
5. Kato T, Iwama Y, Okumura K, Hashimoto H, Ito T, Satake T. Prostaglandin H2 may be the endothelium-derived contracting factor released by acetylcholine in the aorta of the rat. Hypertension. 1990;15:475-481.
6. Katusic ZS, Vanhoutte PM. Superoxide anion is an endothelium-derived contracting factor. Am J Physiol. 1989;257:H33-H37.
7. Linder L, Kiowski W, Buhler FR, Luscher TF. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo: blunted response in essential hypertension. Circulation. 1990;81:1762-1767.
8. Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension. 1993;21:929-933.
9. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med. 1990;323:22-27.
10. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation. 1993;87:1468-1474.
11. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Cyclooxygenase inhibition restores nitric oxide activity in essential hypertension. Hypertension. 1997;29:274-279.
12. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation. 1998;97:2222-2229.
13. Taddei S, Ghiadoni L, Virdis A, Buralli S, Salvetti A. Vasodilation to bradykinin is mediated by an ouabain-sensitive pathway as a compensatory mechanism for impaired nitric oxide availability in essential hypertensive patients. Circulation. 1999;100:1400-1405.
14. Libby P, Sukhova G, Lee RT, Liao JK. Molecular biology of atherosclerosis. Int J Cardiol. 1997;62:S23-S29.
15. Ghiadoni L, Taddei S, Virdis A, Sudano I, Di Legge V, Meola M, Di Venanzio L, Salvetti A. Endothelial function and common carotid artery wall thickening in patients with essential hypertension. Hypertension. 1998;32:25-32.
16. Zeiher AM, Schachlinger V, Hohnloser SH, Saurbier B, Just H. Coronary atherosclerotic wall thickening and vascular reactivity in humans: elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis. Circulation. 1994;89:2525-2532.
17. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000;101:948-954.
18. Schachinger V, Zeiher AM. Prognostic implications of endothelial dysfunction: does it mean anything? Coron Artery Dis. 2001;12:435-443.
19. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001;104:2673-2678.
20. Taddei S, Virdis A, Ghiadoni L, Sudano I, Salvetti A. Effects of antihypertensive drugs on endothelial dysfunction: clinical implications. Drugs. 2002;62:265-284.
21. Taddei S, Virdis A, Ghiadoni L, Magagna A, Favilla S, Pompella A, Salvetti A. Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension. Hypertension. 2001;37:943-948.
22. Taddei S, Virdi A, Ghiadoni L, Magagna A, Pasini AF, Garbin U, Cominacini L, Salvetti A. Effect of calcium antagonist or beta blockade treatment on nitric oxide-dependent vasodilation and oxidative stress in essential hypertensive patients. J Hypertens. 2001;19:1379-1386.
23. McClellan KJ, Jarvis B. Lercanidipine: a review of its use in hypertension. Drugs. 2000;60:1123-1140.
24. Whitney RJ. The measurement of volume changes in human limbs. J Physiol. 1953;121:1-27.
25. Pedrinelli R, Taddei S, Graziadei L, Salvetti A. Vascular responses to ouabain and norepinephrine in low and normal renin hypertension. Hypertension. 1986;8:786-792.
26. Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet. 1989;2:997-1000.
27. Edwards G, Dora KA, Gardener MJ, Garland CJ, Weston AH. K+ is an endothelium-derived hyperpolarizing factor in rat arteries. Nature. 1998;396:269-272.
28. Tonomura Y. (Na+, K+) ATPase in the plasma membrane. In: Tonomura Y. Energy-Transducing ATPase: Structure and Kinetics. Cambridge, UK: Cambridge University Press; 1986.
29. Frei B, England L, Ames BN. Ascorbate is an outstanding antioxidant in human blood plasma. Proc Natl Acad Sci USA. 1989;86:6377-6381.
30. Schultz K, Schultz G. Sodium nitroprusside and other smooth muscle-relaxants increase cyclic GMP levels in rat ductus deferens. Nature. 1977;265:750-751.
31. Jiang ZY, Hunt JV, Wolff SP, Ferrous ion oxidation in the presence of xylenol orange for detection of lipid hydroperoxide in low density lipoprotein. Anal Biochem. 1992;202:384-389.
32. Roberts LJ, Morrow JD. Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med, 2000;28:505-513.
33. Esterbauer H, Cheeseman KH. Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. Methods Enzymol. 1990;186:407-421.
34. Benzie IF, Strain JJ. Ferric reducing/antioxidant power assay: direct measure of total antioxidant activity of biological fluids and modified version for simultaneous measurement of total antioxidant power and ascorbic acid concentration. Methods Enzymol. 1999;299:15-27.
35. Panza JA, Garcia CE, Kilcoyne CM, Quyyumi AA, Cannon RO. Impaired endothelium-dependent vasodilation in patients with essential hypertension: evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation. 1995;91:1732-1738.
36. Beny JL, Brunet PC. Neither nitric oxide nor nitroglycerin accounts for all the characteristics of endothelially mediated vasodilatation of pig coronary arteries. Blood Vessels. 1988;25:308-311.
37. Luscher TF, Yang Z. Calcium antagonists and ACE inhibitors: effect on endothelium and vascular smooth muscle. Drugs. 1993;46(suppl 2):121-132.
38. Rizzoni D, Castellano M, Porteri E, Bettoni G, Muiesan ML, Agabiti Rosei E. Delayed development of hypertension after short-term nitrendipine treatment. Hypertension. 1994;24:131-139.
39. Lupo E, Locher R, Weisser B, Vetter W. In vitro antioxidant activity of calcium antagonists against LDL oxidation compared with alpha-tocopherol. Biochem Biophys Res Commun. 1994;203:1803-1808.
40. Mak IT, Boehme P, Weglicki WB. Antioxidant effects of calcium channel blockers against free radical injury in endothelial cells: correlation of protection with preservation of glutathione levels. Circ Res. 1992;70:1099-1103.
41. Panza JA, Quyyumi AA, Callahan TS, Epstein SE. Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension. J Am Coll Cardiol. 1993;21:1145-1151.
42. Creager MA, Roddy MA. Effect of captopril and enalapril on endothelial function in hypertensive patients. Hypertension. 1994;24:499-505.
43. Kiowski W, Linder L, Nuesch R, Martina B. Effects of cilazapril on vascular structure and function in essential hypertension. Hypertension. 1996;27:371-376.
44. Quyyumi AA. Endothelial function in health and disease: new insights into the genesis of cardiovascular disease. Am J Med. 1998;105:32S-39S.
45. Himmel HM, Whorton AR, Strauss HC. Intracellular calcium, currents, and stimulus-response coupling in endothelial cells. Hypertension. 1993;21:112-127.
46. Nelson MT, Patlak JB, Worley JF, Standen NB. Calcium channels, potassium channels, and voltage dependence of arterial smooth muscle tone. Am J Physiol. 1990;259:C3-C18.
47. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000;101:1899-906.
48. Lichtlen PR, Hugenholtz PG, Raffienbeul W, Hecker H, Jost S, Nikutta P, Deckers JW. Retardation of coronary artery disease in humans by the calcium-channel blocker nifedipine: results of the INTACT study (International Nifedipine Trial on Antiatherosclerotic Therapy). Cardiovasc Drugs Ther. 1990;4(suppl 5):1047-1068.
49. Zanchetti A. The antiatherogenic effects of antihypertensive treatment: trials completed and ongoing. Curr Hypertens Rep. 2001;3:350-359.